Dancann Pharma (DANCAN) Q1 2025 earnings summary

Executive summary

• Q1 2025 was challenging due to increased market competition, regulatory-driven pricing adjustments, and higher product returns, prompting procurement and operational efficiency initiatives.

• Regulatory approval was secured for Bedrolite® and Bedrobinol®, expanding the prescription portfolio and expected to positively impact future sales.

• An exclusive distribution agreement with Tetra Pharm Technologies was signed, enhancing the product pipeline with advanced delivery systems.

• Preparations are underway to launch OTC/DTC botanical extracts, diversifying revenue streams.

Financial highlights

• Q1 2025 net sales were DKK 244, down from DKK 702 in Q1 2024; gross revenue was DKK 558, down from DKK 702.

• EBITDA for Q1 2025 was DKK -2,275, a slight improvement from DKK -2,403 in Q1 2024.

• Operating loss (EBIT) was DKK -2,825, compared to DKK -2,907 in Q1 2024.

• Net loss after tax was DKK -2,928, compared to DKK -3,365 in Q1 2024.

• Cash flow from operating activities was DKK -2,644, compared to DKK -1,290 in Q1 2024.

Outlook and guidance

• Revenue contribution from newly approved products is already incorporated into the 2025 outlook, with further positive sales impact expected.

• Focus remains on disciplined execution, capital efficiency, and delivering operational milestones for long-term value creation.